Archives of Virology

, Volume 158, Issue 1, pp 193–199

Human papillomavirus type 58 L1 virus-like particles purified by two-step chromatography elicit high levels of long-lasting neutralizing antibodies

  • Xixiu Xie
  • Yanchun Liu
  • Ting Zhang
  • Yanying Xu
  • Qifeng Bao
  • Xue Chen
  • Hongyang Liu
  • Xuemei Xu
Brief Report

Abstract

Human papillomavirus (HPV) type 58 is a high-risk type of HPV frequently detected in cervical cancers, especially in Eastern Asia. There are still no commercially available vaccines against HPV 58 infection. High levels of long-lasting neutralizing antibodies are crucial for long-term protection against HPV infection. Here, we have developed a two-step chromatography strategy and have purified highly pure HPV L1 proteins, which form more homogenous and uniform VLPs than those purified by CsCl ultracentrifugation. Low-dosage immunization with HPV 58 L1 VLPs alone or co-administrated with HPV 16 and HPV 18 L1 VLPs is sufficient to induce high levels of long-lasting neutralizing antibodies in mice. Our results suggest that the highly immunogenic HPV 58 L1 VLPs are a good candidate for use in developing effective vaccines against HPV 58 infection.

Supplementary material

705_2012_1465_MOESM1_ESM.pdf (129 kb)
Supplementary material 1 (PDF 129 kb)

References

  1. 1.
    Castellsague X (2007) HPV and cervical cancer in the 2007 report. Vaccine 25(Suppl 3):C1–C230Google Scholar
  2. 2.
    Roden R, Wu TC (2006) How will HPV vaccines affect cervical cancer? Nat Rev Cancer 6:753–763PubMedCrossRefGoogle Scholar
  3. 3.
    Bao YP, Li N, Smith JS, Qiao YL (2008) Human papillomavirus type-distribution in the cervix of Chinese women: a meta-analysis. Int J STD AIDS 19:106–111PubMedCrossRefGoogle Scholar
  4. 4.
    Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, Tay EH, Garcia P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Dillner J, Joura EA, Kurman RJ, Majewski S, Munoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan J, Lupinacci LC, Giacoletti KE, Sings HL, James M, Hesley TM, Barr E (2009) The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16–26 years. J Infect Dis 199:926–935PubMedCrossRefGoogle Scholar
  5. 5.
    Kemp TJ, Hildesheim A, Safaeian M, Dauner JG, Pan Y, Porras C, Schiller JT, Lowy DR, Herrero R, Pinto LA (2011) HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection. Vaccine 29:2011–2014PubMedCrossRefGoogle Scholar
  6. 6.
    Zhang T, Xu Y, Qiao L, Wang Y, Wu X, Fan D, Peng Q, Xu X (2010) Trivalent Human Papillomavirus (HPV) VLP vaccine covering HPV type 58 can elicit high level of humoral immunity but also induce immune interference among component types. Vaccine 28:3479–3487PubMedCrossRefGoogle Scholar
  7. 7.
    Giannini SL, Hanon E, Moris P, Van Mechelen M, Morel S, Dessy F, Fourneau MA, Colau B, Suzich J, Losonksy G, Martin MT, Dubin G, Wettendorff MA (2006) Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 24:5937–5949PubMedCrossRefGoogle Scholar
  8. 8.
    Xie M, Li S, Shen W, Li Z, Zhuang Y, Mo X, Gu Y, Wu T, Zhang J, Xia N (2009) Expression, purification and immunogenicity analysis of HPV type 18 virus-like particles from Escherichia coli]. Sheng wu gong cheng xue bao. Chin J Biotechnol 25:1082Google Scholar
  9. 9.
    Reed LJ, Muench H (1938) A simple method of estimating fifty percent endpoints. Am J Hyg 27:493–497Google Scholar
  10. 10.
    Combita AL, Touze A, Bousarghin L, Christensen ND, Coursaget P (2002) Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses. J Virol 76:6480–6486PubMedCrossRefGoogle Scholar
  11. 11.
    Fang NX, Frazer IH, Fernando GJ (2000) Differences in the post-translational modifications of human papillomavirus type 6b major capsid protein expressed from a baculovirus system compared with a vaccinia virus system. Biotechnol Appl Biochem 32(Pt 1):27–33PubMedCrossRefGoogle Scholar
  12. 12.
    Rose RC, Bonnez W, Da Rin C, McCance DJ, Reichman RC (1994) Serological differentiation of human papillomavirus types 11, 16 and 18 using recombinant virus-like particles. J Gen Virol 75(Pt 9):2445–2449PubMedCrossRefGoogle Scholar
  13. 13.
    Burova E, Ioffe E (2005) Chromatographic purification of recombinant adenoviral and adeno-associated viral vectors: methods and implications. Gene Ther 12(Suppl 1):S5–S17PubMedCrossRefGoogle Scholar
  14. 14.
    Huhti L, Blazevic V, Nurminen K, Koho T, Hytonen VP, Vesikari T (2010) A comparison of methods for purification and concentration of norovirus GII-4 capsid virus-like particles. Arch Virol 155:1855–1858PubMedCrossRefGoogle Scholar
  15. 15.
    Suzich JA, Ghim SJ, Palmer-Hill FJ, White WI, Tamura JK, Bell JA, Newsome JA, Jenson AB, Schlegel R (1995) Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci USA 92:11553–11557CrossRefGoogle Scholar
  16. 16.
    Roteli-Martins C, Naud P, De Borba P, Teixeira J, De Carvalho N, Zahaf T, Sanchez N, Geeraerts B, Descamps D (2012) Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up. Human Vaccines Immunotherapeutics 8:365–372CrossRefGoogle Scholar
  17. 17.
    Villa L, Costa R, Petta C, Andrade R, Paavonen J, Iversen O, Olsson S, Høye J, Steinwall M, Riis-Johannessen G (2006) High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 95:1459–1466PubMedCrossRefGoogle Scholar
  18. 18.
    Pastrana DV, Buck CB, Pang YY, Thompson CD, Castle PE, FitzGerald PC, Kruger Kjaer S, Lowy DR, Schiller JT (2004) Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology 321:205–216PubMedCrossRefGoogle Scholar
  19. 19.
    Dessy FJ, Giannini SL, Bougelet CA, Kemp TJ, David M, Poncelet SM, Pinto LA, Wettendorff MA (2008) Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine. Hum Vaccin 4:425–434PubMedCrossRefGoogle Scholar
  20. 20.
    Harro CD, Pang YY, Roden RB, Hildesheim A, Wang Z, Reynolds MJ, Mast TC, Robinson R, Murphy BR, Karron RA, Dillner J, Schiller JT, Lowy DR (2001) Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst 93:284–292PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • Xixiu Xie
    • 1
  • Yanchun Liu
    • 1
  • Ting Zhang
    • 1
  • Yanying Xu
    • 1
  • Qifeng Bao
    • 1
  • Xue Chen
    • 1
  • Hongyang Liu
    • 1
  • Xuemei Xu
    • 1
  1. 1.Department of Biophysics and Structural BiologyInstitute of Basic Medical Sciences Chinese Academy of Medical Sciences, School of Basic Medicine Peking Union Medical CollegeBeijingChina

Personalised recommendations